pentobarbital increases toxicity of buprenorphine, extended-performing injection by pharmacodynamic synergism. Modify Therapy/Check Intently. Coadministration of buprenorphine and benzodiazepines or other CNS depressants improves chance of adverse reactions including overdose, respiratory melancholy, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases.
pentobarbital will decrease the extent or outcome of bortezomib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
pentobarbital will decrease the level or impact of quinine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Not known.
Physical exercise warning when a barbiturate is administered to a nursing girl; little quantities of barbiturates are excreted in the milk
pentobarbital will lower the extent or influence of copyright topical by influencing hepatic enzyme CYP2B6 metabolism. Minor/Significance Unidentified.
pentobarbital will reduce the level or outcome of fentanyl intranasal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead sodium pentobarbital to a minimize in fentanyl plasma concentrations, deficiency of efficacy or, quite possibly, progress of a withdrawal syndrome within a affected person who has made Bodily dependence to fentanyl.
With therapeutic doses of TCAs, barbiturates enhance metabolism and reduce blood concentrations of TCAs.
lasmiditan, pentobarbital. Both increases effects of the opposite by sedation. Use Warning/Check. Coadministration of lasmiditan along with other CNS depressant drugs, including Liquor haven't been evaluated in clinical studies. Lasmiditan may possibly cause sedation, and also other cognitive and/or neuropsychiatric adverse reactions.
pentobarbital will decrease the level or effect of zolpidem by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unfamiliar.
pentobarbital will minimize the level or outcome of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will reduce the extent or effect of atazanavir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Mysterious.
Drugs that demand prior authorization. This restriction necessitates that distinct scientific criteria be fulfilled ahead of the approval on the prescription.
Barbiturates can induce hepatic microsomal enzymes resulting in greater metabolism and reduced anticoagulant reaction of oral anticoagulants (eg, warfarin, acenocoumarol, dicumarol, and phenprocoumon); patients stabilized on anticoagulant therapy may possibly require dosage adjustments if barbiturates are included to or withdrawn from their dosage regimen
Withdrawal signs or symptoms happen in infants born to mothers who receive barbiturates through the entire final trimester of pregnancy